Sibutramine
- Generic Name
- Sibutramine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26ClN
- CAS Number
- 106650-56-0
- Unique Ingredient Identifier
- WV5EC51866
- Background
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October ...
- Indication
For the treatment of obesity.
- Associated Conditions
- Obesity
- Associated Therapies
- -
A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT01597609
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)
- Conditions
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 200
- Registration Number
- NCT01475019
- Locations
- 🇬🇷
Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece
Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 174
- Registration Number
- NCT01184560
- Locations
- 🇰🇷
GachonGill Medical Center, Inchon, Namdong-gu, Korea, Republic of
Studying the Effects of Sibutramine on Eating Behavior
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 14
- Registration Number
- NCT01170364
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
A Weight Loss Study in Overweight Men and Women
- Conditions
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2011-06-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 343
- Registration Number
- NCT00993421
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 60
- Registration Number
- NCT00941382
- Locations
- 🇲🇽
Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico
Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients
- Conditions
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Laval University
- Target Recruit Count
- 45
- Registration Number
- NCT00729963
Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives
- Conditions
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2008-05-19
- Lead Sponsor
- Abbott
- Target Recruit Count
- 171
- Registration Number
- NCT00679653
Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population
- First Posted Date
- 2008-05-14
- Last Posted Date
- 2008-05-14
- Lead Sponsor
- Abbott
- Target Recruit Count
- 103
- Registration Number
- NCT00677391
Treatment of Binge Eating in Obese Patients in Primary Care
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Yale University
- Target Recruit Count
- 104
- Registration Number
- NCT00537810
- Locations
- 🇺🇸
Yale-New Haven Hospital (YNHH) Primary Care Center (PCC), New Haven, Connecticut, United States
🇺🇸Yale Internal Medicine Associates (YIMA), New Haven, Connecticut, United States
🇺🇸Yale Psychiatric Research at Congress Place, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.